Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025

Core Insights - Defence Therapeutics Inc. will present new scientific data on its Accum® technology at the World ADC Conference in San Diego, highlighting its potential to enhance the efficacy of antibody-drug conjugates (ADCs) [1][2] Company Overview - Defence Therapeutics is a biotechnology company focused on drug delivery technologies, specifically developing next-generation ADC products using its proprietary Accum® platform [5] - The Accum® technology is designed to improve intracellular delivery and endosomal escape of therapeutic payloads, addressing limitations of current ADCs and enabling higher potency with reduced off-target toxicity [2][5] Scientific Findings - New results to be presented at the conference demonstrate Accum®'s ability to significantly improve the therapeutic index of ADCs, allowing for more efficient delivery of toxic payloads directly into cancer cells [2][3] - The Chief Scientific Officer of Defence Therapeutics expressed excitement about sharing these findings with the scientific community and advancing research towards next-generation targeted therapies [3] Conference Details - The World ADC Conference is a premier event for ADC innovation, featuring 1,400 industry attendees and over 170 world-class speakers, providing significant networking opportunities [4]